Diagnostics

A shocking $90M guidance cut and a securities probe at Myriad Genetics reveal more than a bad quarter; they expose deep cracks in the genetic testing market.

Revvity's new SuperFlex system isn't just a new device; it's a strategic move to decentralize preeclampsia testing and capture an underserved market.

Revenue missed and its stock plunged, but Quanterix is betting on a new C-suite and its Alzheimer's test to navigate market headwinds and deliver on its promise.

With a key leadership hire, UK's Reacta Healthcare leverages its pharma-grade advantage to scale R&D and transform the global food allergy testing landscape.

With at-home PCR tests and AI-driven insights, Petwealth is building a decentralized health network for pets, challenging the traditional vet care model.

A Utah biotech's new blood test can identify the exact brain cells dying in diseases like Alzheimer's, a major leap beyond today's diagnostics.

Vexev’s AI-powered robotic ultrasound platform just raised $6M to tackle the specialist shortage and transform cardiovascular disease diagnostics for millions.

Breakthroughs in blood-based diagnostics are revolutionizing Alzheimer's care, but a new analysis reveals that compassionate communication is just as vital.

As a major cyclospora outbreak sweeps the U.S., Roche's new research-only PCR tests provide a critical, behind-the-scenes tool for public health.

GRAIL’s Galleri test shows stunning clinical results and sales growth, but staggering financial losses and a looming FDA review create a high-wire act for innovation.

The new cvi42 v6.5 platform automates complex analyses, promising to slash diagnostic times and empower patients with clearer insights into their heart health.

A new 10-minute test aims to move brain health from the research lab to your phone, creating a 'Brain Score' that could redefine performance and longevity.

As Tecan prepares to unveil its H1 2026 results, the numbers will offer more than a corporate health check—they are a key signal for the entire lab automation industry's recovery.

With a major cash infusion, CND Life Sciences is set to scale its skin-based test for Parkinson's, signaling a shift from subjective diagnosis to objective data.

By partnering with major CROs, Revolune is tackling a key bottleneck in advanced tissue analysis. This new ecosystem could change how labs of all sizes innovate.

For millions with back pain, diagnosis is a guess. Aclarion's AI platform promises a 97% success rate, and it's expanding with a key Indiana partnership.

A new strategic alliance aims to dismantle geographic barriers in oncology by decentralizing diagnostics, a move with profound implications for patient access.

LabPMM's new global KMT2A MRD test offers ultra-sensitive monitoring for aggressive leukemias, aiming to improve patient outcomes and streamline trials for menin inhibitors.

DeepHealth's newly FDA-cleared AI for breast ultrasound promises to standardize a complex exam, boost accuracy, and reduce radiologist workload.

As CapsoVision preps its Q2 report, investors look past the numbers to its AI-driven pipeline, a key test of its strategy to reshape GI diagnostics.